Get the Stockscreener App
12.14
5.67%
-0.73
4 D Molecular Therapeutics Inc stock is traded at $12.14, with a volume of 794.53K.
It is down -5.67% in the last 24 hours and down -11.77% over the past month.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
See More
Previous Close:
$12.87
Open:
$12.84
24h Volume:
794.53K
Relative Volume:
0.81
Market Cap:
$670.66M
Revenue:
$88.24M
Net Income/Loss:
$-160.90M
P/E Ratio:
-4.5567
EPS:
-2.6642
Net Cash Flow:
$-129.35M
1W Performance:
-8.93%
1M Performance:
-11.77%
6M Performance:
+20.68%
1Y Performance:
+20.32%
1-Day Range:
$12.00
$12.84
1-Week Range:
$11.99
$13.47
52-Week Range:
$6.96
$16.93
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
12.14 | 670.66M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-14-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-31-26 | Initiated | B. Riley Securities | Buy |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Nov-07-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com India
Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com Nigeria
4D molecular therapeutics CEO David Kirn sells $753k in company stock - Investing.com Nigeria
Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com UK
4D molecular therapeutics CEO David Kirn sells $753k in company stock - Investing.com India
CEO David Kirn sells 58,061 and 272 shares of 4D Molecular Therapeutics (FDMT) under a trading plan. - Stock Titan
4D Molecular Therapeutics Officer David Kirn Files Form 144 for Sale of 58,333 Shares - Kalkine Media
Officer David Kirn plans to sell 58,333 shares of 4D Molecular Therapeutics (FDMT). - Stock Titan
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock By Investing.com - Investing.com Nigeria
Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com India
Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com UK
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com
4D Molecular (FDMT) legal chief exercises options, then sells 1,635 shares - Stock Titan
4D Molecular Therapeutics (Nasdaq:FDMT)Stock Analysis - Simply Wall Street
4D molecular therapeutics CEO Kirn sells $811,003 in stock - Investing.com
4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics (FDMT) CEO sells 58K shares under preset plan - Stock Titan
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing - Yahoo Finance
4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com UK
Insider at 4D Molecular (NASDAQ: FDMT) plans new stock sale after recent trades - Stock Titan
4D Molecular Therapeutics Grants RSUs to Seven New Non-Executive Employees - quiverquant.com
Seven new employees get 96,000 stock units from 4DMT - stocktitan.net
4DMT Announces New Employment Inducement Grants - GlobeNewswire
FDMT: Phase III data for 4D-150 in wet AMD and DME expected next year, targeting major treatment shifts - TradingView
FDMT: 4D-150 targets a paradigm shift in wet AMD with major phase III data expected next year - TradingView
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com Nigeria
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com India
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 - Investing.com
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief trades 584 shares at $14 - Stock Titan
4D Molecular Therapeutics Chief Legal Officer Scott Bizily disposes of 584 common shares for $8,176 - Bitget
4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat
4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME - Bitget
4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn
David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan
HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com India
4D Molecular Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4 D Molecular Therapeutics Inc Stock (FDMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| David Kirn | Officer |
Oct 05 '26 |
Proposed Sale |
12.92 |
58,333 |
753,662 |
0 |
| Bizily Scott | Chief Legal Officer |
Sep 16 '26 |
Sale |
13.65 |
1,635 |
22,318 |
8,617 |
| Bizily Scott | Chief Legal Officer |
Sep 16 '26 |
Option Exercise |
4.14 |
1,635 |
6,769 |
10,252 |
| Kirn David | See Remarks |
Sep 14 '26 |
Sale |
13.90 |
58,333 |
811,004 |
767,486 |
| David Kirn | Officer |
Sep 14 '26 |
Proposed Sale |
13.76 |
58,333 |
802,662 |
0 |
| Bizily Scott | Chief Legal Officer |
Sep 01 '26 |
Option Exercise |
6.49 |
584 |
3,790 |
9,201 |
| Bizily Scott | Chief Legal Officer |
Sep 01 '26 |
Sale |
14.00 |
584 |
8,176 |
8,617 |
| Kirn David | See Remarks |
Aug 19 '26 |
Sale |
15.75 |
69,076 |
1,088,273 |
825,819 |
| David Kirn | Officer |
Aug 19 '26 |
Proposed Sale |
16.76 |
69,076 |
1,157,714 |
0 |
| Kirn David | See Remarks |
Aug 19 '26 |
Option Exercise |
4.14 |
50,000 |
207,000 |
894,895 |
2.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):